» Articles » PMID: 8608500

Surgical Resection of Colorectal Carcinoma Metastases to the Liver. A Prognostic Scoring System to Improve Case Selection, Based on 1568 Patients. Association Française De Chirurgie

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1996 Apr 1
PMID 8608500
Citations 510
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Five-year survival rates after resection of liver metastases from colorectal carcinoma are close to 25%. Recurrences occur in two-thirds of the patients after surgery. Selection of patients likely to benefit from surgery remains controversial and subjective.

Methods: Data from 1568 patients with resected liver metastases from colorectal carcinoma were collected. The prognostic value of different factors was studied through uni- and multivariate analyses. A scoring system was developed including the most relevant factors.

Results: Two- and 5-year survival rates were 64% and 28%, respectively, and were affected by: age; size of largest metastasis or CEA level; stage of the primary tumor; disease free interval; number of liver nodules; and resection margin. Giving one point to each factor, the population was divided into three risk groups three risk groups with different 2-year survival rates: 0-2 (79%), 3-4 (60%), 5-7 (43%).

Conclusions: A simple prognostic scoring system was proposed to evaluate the chances for cure of patients after resection of liver metastases from colorectal carcinoma. The comparison between expected survival and estimated operative risk can help determine on an objective basis whether surgery is worthwhile. This system needs further prospective validation.

Citing Articles

Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations.

Parikh P, Bahl A, Sharma G, Pramanik R, Wadhwa J, Bajpai P South Asian J Cancer. 2025; 13(4):287-295.

PMID: 40060353 PMC: 11888815. DOI: 10.1055/s-0044-1791689.


-Beppu Classification: A New Recurrence Risk Classification System Incorporating the Beppu Score and Status for Colorectal Liver Metastases.

Tajiri T, Mima K, Beppu T, Hayashi H, Horino T, Adachi Y Cancers (Basel). 2025; 17(4).

PMID: 40002236 PMC: 11853466. DOI: 10.3390/cancers17040640.


2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinoma.

Stecca C, Chowdhury D, Blais N, Alimohamed N, Wood L, Canil C Can Urol Assoc J. 2024; 18(12):379-390.

PMID: 39641956 PMC: 11623328. DOI: 10.5489/cuaj.8946.


Inverse Correlation between -Carrying Abundance in Colorectal Cancer Liver Metastases and the Number of Organs Involved in Recurrence.

Shigematsu Y, Saito R, Kanda H, Takahashi Y, Takeuchi K, Takahashi S Cancers (Basel). 2024; 16(17).

PMID: 39272861 PMC: 11394077. DOI: 10.3390/cancers16173003.


Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis.

Li W, Lan J, Zhou C, Yang R, Wang J, He J Ann Med. 2024; 56(1):2396559.

PMID: 39247989 PMC: 11385633. DOI: 10.1080/07853890.2024.2396559.